SG11201809838VA - Method of treating lower tract urothelial cancer - Google Patents
Method of treating lower tract urothelial cancerInfo
- Publication number
- SG11201809838VA SG11201809838VA SG11201809838VA SG11201809838VA SG11201809838VA SG 11201809838V A SG11201809838V A SG 11201809838VA SG 11201809838V A SG11201809838V A SG 11201809838VA SG 11201809838V A SG11201809838V A SG 11201809838VA SG 11201809838V A SG11201809838V A SG 11201809838VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lexington
- lower tract
- christo
- pher
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 206010044412 transitional cell carcinoma Diseases 0.000 title abstract 4
- 230000000340 anti-metabolite Effects 0.000 abstract 2
- 229940100197 antimetabolite Drugs 0.000 abstract 2
- 239000002256 antimetabolite Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229960005277 gemcitabine Drugs 0.000 abstract 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 2
- 208000023747 urothelial carcinoma Diseases 0.000 abstract 2
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 230000029305 taxis Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Materials For Medical Uses (AREA)
- Epoxy Compounds (AREA)
- Saccharide Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333151P | 2016-05-06 | 2016-05-06 | |
| US201762443614P | 2017-01-06 | 2017-01-06 | |
| PCT/US2017/031445 WO2017193098A1 (en) | 2016-05-06 | 2017-05-05 | Method of treating lower tract urothelial cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809838VA true SG11201809838VA (en) | 2018-12-28 |
Family
ID=60203435
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913416PA SG10201913416PA (en) | 2016-05-06 | 2017-05-05 | Method of treating lower tract urothelial cancer |
| SG11201809838VA SG11201809838VA (en) | 2016-05-06 | 2017-05-05 | Method of treating lower tract urothelial cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913416PA SG10201913416PA (en) | 2016-05-06 | 2017-05-05 | Method of treating lower tract urothelial cancer |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20190388338A1 (enExample) |
| EP (2) | EP3452053B1 (enExample) |
| JP (3) | JP7712055B2 (enExample) |
| KR (2) | KR20220123317A (enExample) |
| CN (2) | CN118453872A (enExample) |
| AU (1) | AU2017261371B2 (enExample) |
| CA (1) | CA3023274A1 (enExample) |
| ES (1) | ES2940227T3 (enExample) |
| FI (1) | FI3452053T3 (enExample) |
| HR (1) | HRP20221544T1 (enExample) |
| HU (1) | HUE060965T2 (enExample) |
| IL (2) | IL295592A (enExample) |
| LT (1) | LT3452053T (enExample) |
| MX (2) | MX389296B (enExample) |
| NZ (3) | NZ787824A (enExample) |
| PL (1) | PL3452053T3 (enExample) |
| PT (1) | PT3452053T (enExample) |
| RS (1) | RS64032B1 (enExample) |
| RU (2) | RU2022100624A (enExample) |
| SG (2) | SG10201913416PA (enExample) |
| SI (1) | SI3452053T1 (enExample) |
| SM (1) | SMT202300047T1 (enExample) |
| WO (1) | WO2017193098A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY198562A (en) | 2015-11-03 | 2023-09-05 | Janssen Biotech Inc | Antibodies specifically binding pd-1 and their uses |
| KR102576042B1 (ko) | 2016-10-11 | 2023-09-07 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| JP7391009B2 (ja) | 2017-07-25 | 2023-12-04 | タリス バイオメディカル エルエルシー | 腫瘍転移を処置する方法 |
| US10792297B2 (en) | 2017-11-08 | 2020-10-06 | Taris Biomedical Llc | Methods of treatment and maintenance therapy for bladder cancer using gemcitabine |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY30915A1 (es) * | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
| CA2765734C (en) | 2009-06-26 | 2016-12-13 | Taris Biomedical, Inc. | Implantable drug delivery devices and methods of making the same |
| LT2512581T (lt) | 2009-12-17 | 2021-03-25 | Taris Biomedical Llc | Intravezikalinio suderinamumo implantuojamas medicininis įtaisas |
| US20130266659A1 (en) * | 2010-06-02 | 2013-10-10 | Neil P. Desai | Methods of treating bladder cancer |
| EP3795121A1 (en) | 2010-08-05 | 2021-03-24 | TARIS Biomedical LLC | Ureteral stent drug delivery device |
| RU2598057C2 (ru) | 2011-02-04 | 2016-09-20 | ТАРИС Биомедикал ЛЛК | Имплантируемое устройство для контролируемого высвобождения лекарственного средства с низкой растворимостью |
| CN111420032A (zh) | 2012-03-29 | 2020-07-17 | 阿尔托生物科学有限公司 | 用于治疗肿瘤的方法 |
| BR112015004110A2 (pt) | 2012-08-31 | 2017-07-04 | Taris Biomedical Llc | sistemas e métodos de distribuição de drogas para tratamento de próstata |
| SG11201501424SA (en) * | 2012-08-31 | 2015-03-30 | Taris Biomedical Llc | Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin |
| US10137287B2 (en) | 2013-03-05 | 2018-11-27 | Taris Biomedical Llc | Drug delivery devices and methods for controlled drug release through device orifice |
| KR102398262B1 (ko) | 2013-03-15 | 2022-05-13 | 타리스 바이오메디컬 엘엘씨 | 약물-투과성 구성요소를 가지는 약물 전달 장치 및 방법 |
| EP2968120A1 (en) | 2013-03-15 | 2016-01-20 | TARIS Biomedical LLC | Drug delivery devices and methods for drug delivery |
| KR102385603B1 (ko) | 2013-08-19 | 2022-04-11 | 타리스 바이오메디컬 엘엘씨 | 다중 유닛 약물 전달 장치 및 방법 |
| SMT202500385T1 (it) | 2014-03-06 | 2025-11-10 | Taris Biomedical Llc | Sistemi e metodi di erogazione di farmaco per il trattamento del cancro della vescica con gemcitabina |
| ES2728504T3 (es) | 2014-06-26 | 2019-10-25 | Taris Biomedical Llc | Dispositivos de administración de fármacos por vía intravesical y métodos que comprenden sistemas matriciales polímero-fármaco elásticos |
| US10894150B2 (en) | 2015-04-23 | 2021-01-19 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
-
2017
- 2017-05-05 CN CN202410626384.1A patent/CN118453872A/zh active Pending
- 2017-05-05 SG SG10201913416PA patent/SG10201913416PA/en unknown
- 2017-05-05 HR HRP20221544TT patent/HRP20221544T1/hr unknown
- 2017-05-05 AU AU2017261371A patent/AU2017261371B2/en active Active
- 2017-05-05 HU HUE17793523A patent/HUE060965T2/hu unknown
- 2017-05-05 CA CA3023274A patent/CA3023274A1/en active Pending
- 2017-05-05 NZ NZ787824A patent/NZ787824A/en unknown
- 2017-05-05 IL IL295592A patent/IL295592A/en unknown
- 2017-05-05 NZ NZ787786A patent/NZ787786A/en unknown
- 2017-05-05 US US16/099,179 patent/US20190388338A1/en active Pending
- 2017-05-05 RS RS20230163A patent/RS64032B1/sr unknown
- 2017-05-05 FI FIEP17793523.6T patent/FI3452053T3/fi active
- 2017-05-05 SI SI201731301T patent/SI3452053T1/sl unknown
- 2017-05-05 SM SM20230047T patent/SMT202300047T1/it unknown
- 2017-05-05 RU RU2022100624A patent/RU2022100624A/ru unknown
- 2017-05-05 EP EP17793523.6A patent/EP3452053B1/en active Active
- 2017-05-05 ES ES17793523T patent/ES2940227T3/es active Active
- 2017-05-05 RU RU2018142908A patent/RU2764747C2/ru active
- 2017-05-05 PT PT177935236T patent/PT3452053T/pt unknown
- 2017-05-05 KR KR1020227028547A patent/KR20220123317A/ko not_active Ceased
- 2017-05-05 WO PCT/US2017/031445 patent/WO2017193098A1/en not_active Ceased
- 2017-05-05 JP JP2018558199A patent/JP7712055B2/ja active Active
- 2017-05-05 LT LTEPPCT/US2017/031445T patent/LT3452053T/lt unknown
- 2017-05-05 SG SG11201809838VA patent/SG11201809838VA/en unknown
- 2017-05-05 EP EP22212024.8A patent/EP4209221A1/en active Pending
- 2017-05-05 CN CN201780040391.1A patent/CN109475571A/zh active Pending
- 2017-05-05 IL IL262746A patent/IL262746B/en unknown
- 2017-05-05 MX MX2018013432A patent/MX389296B/es unknown
- 2017-05-05 NZ NZ748252A patent/NZ748252A/en unknown
- 2017-05-05 PL PL17793523.6T patent/PL3452053T3/pl unknown
- 2017-05-05 KR KR1020187035297A patent/KR102435709B1/ko active Active
-
2018
- 2018-11-01 MX MX2021013461A patent/MX2021013461A/es unknown
-
2021
- 2021-10-21 JP JP2021172052A patent/JP2022009327A/ja not_active Withdrawn
-
2023
- 2023-12-07 JP JP2023206570A patent/JP2024028881A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201809838VA (en) | Method of treating lower tract urothelial cancer | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201903155XA (en) | Pharmaceutical compounds | |
| SG11201805281YA (en) | Resource allocation for computer processing | |
| SG11201903892UA (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201903236SA (en) | Lasofoxifene treatment of er+ breast cancer | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer | |
| SG11201907439QA (en) | An anatomical adaptable drape device | |
| SG11201909840TA (en) | Treatment of epithelial cysts by intracystic injection of antineoplastic particles | |
| SG11201909107YA (en) | Stenosis treatment |